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Background:  Despite  well-controlled  low-density  lipoprotein  cholesterol  (LDL-C),  hypertriglyceridemia
is  an  independent  predictor  of coronary  events.  We  investigated  the  risk  of  atherosclerotic  cardiovascular
disease  through  examining  the  relation  between  triglyceride  (TG)  metabolism  and  LDL-heterogeneity  as
assessed  by  polyacrylamide-gel  electrophoresis  (PAGE).
Methods and  results:  Estimated  LDL-particle  size  [relative  LDL  migration  (LDL-Rm  value)]  measured  by
PAGE  with  the  LipoPhor  system  (Joko,  Tokyo,  Japan)  was  evaluated  in  645  consecutive  patients  with
one  additional  risk  factor  for atherosclerotic  cardiovascular  disease.Multivariate  regression  analysis  after
adjustments  for  traditional  risk  factors  revealed  an elevated  triglyceride-rich  lipoproteins  (TRLs)-related
markers  [TG,  remnant-like  particle  cholesterol  (RLP-C),  very  LDL  (VLDL)  fraction,  apolipoprotein  (apo)
C-II,  and  apo  C-III]  level  to  be  an independent  predictor  of  smaller-size  LDL-particle  size, both  in the
overall  population,  and in  a subset  of  patients  with  serum  LDL-C  <100  mg/dL.  Even  among  the  patients
with  LDL-C  levels  <100  mg/dL,  the  serum  levels  of  atherogenic  lipid  markers  in those  with  a  LDL-Rm
value  ≥0.40,  suggesting  the  presence  of  large  amounts  of  small-dense  LDL  and  upper  limit  (mean  +  2
standard  deviation)  in  this  population,  were  signiﬁcantly  higher  than  in those  with a LDL-Rm  value
<0.40.  Moreover,  the  serum  levels  of  TRLs-related  markers  showed  high  accurate  area  under  the receiver-
operating  characteristic  curve  (TG,  0.896;  RLP-C,  0.875;  VLDL  fraction,  0.803;  apo  C-II,  0.778;  and  apo  C-III,
0.804,  respectively)  in  terms  of  evaluation  of the  indicators  of  LDL-Rm  value  ≥0.40.
Conclusion: To further  reduce  the  risk  of atherosclerotic  cardiovascular  disease,  it may  be  of  partic-
ular  importance  to pay  attention  not  only  to the quantitative  change  in  the  serum  LDL-C,  but  also
TG-metabolism  associated  with  LDL-heterogeneity.  Combined  evaluation  of  TRLs-related  markers  and
LDL-Rm  value  may  be  useful  for assessing  the risk  of  atherosclerotic  cardiovascular  disease.
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Large observational studies clearly show that elevated triglyc-
ride (TG) levels are associated with increased coronary artery
isease (CAD) risk [1]. Moreover, in recent years evidence of the
mportance of the substances associated with hypertriglyceridemia
s residual risks of CAD has been increasing even in successful
ow-density lipoprotein cholesterol (LDL-C) reduction trials [2]. TG
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metabolites, i.e. chylomicrons, very low density lipoprotein (VLDL),
and remnant-like particle cholesterol (RLP-C), which are TG-rich
lipoproteins (TRLs), and, apolipoprotein (apo) CII and apo CII which
are involved in the metabolic process, etc. have been demonstrated
to be involved in the progression of atherosclerosis [3].
In  addition, conversion of LDL to small particles (small dense
LDL, sd-LDL), which hypertriglyceridemia causes, is a powerful pro-
moter of atherosclerotic cardiovascular disease, especially CAD,
and has also been reported to be a predictor of ischemic cardiac
events [4].Density gradient ultracentrifugation, nondenaturing gradient
gel electrophoresis, and nuclear magnetic resonance spectroscopy
are the methods that are usually employed to measure LDL-particle
size; but they are difﬁcult to apply in clinical settings due to
vier Ltd. All rights reserved.
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Patients
We  excluded 55 subjects from the analysis because of missing
laboratory data. Therefore, ﬁnally, 645 subjects were included in
HDL LDL VLDL
a
bS. Tani et al. / Journal of
heir cost and complexity [5]. On the other hand, estimation of
DL-particle size based on relative LDL migration (LDL-Rm) dur-
ng polyacrylamide-gel electrophoresis (PAGE) has been reported.
urrently, the Lipoprint system, also based on the PAGE system,
s used for estimation of the LDL particle size by a simple pro-
edure in the clinical setting, and has been shown to carry high
iagnostic accuracy [6]. In Japan, however, the Lipoprint system is
ot commercially available at present. We  used the LipoPhor sys-
em (Joko, Tokyo, Japan) for the evaluation of the LDL-particle size
n this study. High correlation of the assay results between the two
ethods has been reported [5,7,8].
The purpose of this study was to evaluate the usefulness of
easuring LDL-Rm value as an index of the LDL-particle size by
xamining the relation between the serum levels of TRLs-related
arkers (TG, VLDL fraction, RLP-C, apo C-II, and apo C-III) and the
DL-Rm value by the hospital-based cross-sectional study method,
nd furthermore, to reevaluate the risk of CAD through examining
he relations between TG-metabolism and LDL-particle size.
ethods
tudy  design and populations
This  study was designed as a hospital-based cross-sectional
tudy to investigate the relationships between the serum levels
f TRLs-related markers as indicators of the risk of atherosclerotic
ardiovascular disease and LDL-heterogeneity in patients with the
resence of one or more risk factors for atherosclerosis.
The study was conducted on a sample of 700 consecutive
utpatients who had undergone regular examinations and blood
xaminations at Cardiovascular Center, Surugadai Nihon University
ospital between April 2009 and October 2009.
The criterion for patient registration in the cross-sectional study
as the presence of one or more risk factors for atherosclero-
is. The diagnostic criteria for the coronary risk factors that we
sed in this study analysis were: a diagnosis of hypertension was
ade when systolic pressure was 140 mmHg  or diastolic pres-
ure was 90 mmHg, or above, or taking medication. Diabetes was
eﬁned as a fasting plasma glucose concentrations ≥126 mg/dL and
emoglobin (Hb) A1c ≥6.5% [according to the National Glycohe-
oglobin Standardization Program (NGSP)], or current treatment
ith anti-diabetic agents. A diagnosis of dyslipidemia was  made
hen the LDL-C level was 140 mg/dL or above, the TG level
as 150 mg/dL or above, or the high-density lipoprotein choles-
erol (HDL-C) level was less than 40 mg/dL, or if the patient was
lready on lipid-lowering medication. The severity of chronic kid-
ey disease (CKD) was determined on the basis of the estimated
lomerular ﬁltration rate (GFR) using the abbreviated Modiﬁca-
ion of Diet in Renal Disease (MDRD) Study equation modiﬁed by a
apanese coefﬁcient [9].
The Surugadai Nihon University Hospital Ethics Committee
pproved all study design and purpose.
easurement of laboratory parameters
Fasting blood samples were collected early in the morning after
 12-h fast. The serum total cholesterol (TC), HDL-C, and TG lev-
ls were measured by the standard methods. LDL-C levels were
stimated by using the Friedewald formula [10]. The RLP-C level
as measured by an immunoadsorption assay (SRL Co., Ltd., Tokyo,
apan). The VLDL fraction was measured by performing PAGE elec-
rophoresis using the LipoPhor system. The serum apo level was
etermined by turbidimetric latex agglutination assays (Daiichi
ure Chemicals Co., Ltd., Tokyo, Japan). The malondialdehyde-
odiﬁed  LDL (MDA-LDL) level was measured by an enzyme-linkedology 63 (2014) 60–68 61
immunosorbent assay (SRL Co., Ltd.). The high sensitivity C-reactive
protein (hs-CRP) level was measured by a nephelometric assay
(Behring Diagnostic, Marburg, Germany).
Measurement of LDL-Rm value
LDL-Rm value, an indicator of LDL-particle size, was  measured
relative to the mobility value of LDL by performing PAGE with
the LipoPhor system. LDL-Rm value was calculated as the distance
between the VLDL peak and the LDL peak divided by the distance
between the VLDL peak and the HDL peak (Fig. 1). Several studies
have reported that an LDL-Rm value of 0.40 or more suggests the
presence of a large amount of sd-LDL in the LDL fraction [11–13].
The subjects of this study were not healthy persons in the gen-
eral population, but the upper limit of the reference interval of
the subjects’ LDL-Rm values (mean ± 2 Standard deviation [cov-
ering 95% of the population: 0.350 ± 0.058]) was 0.408, and it was
approximately the same as the 0.40 reported above. Accordingly,
we conducted this study on the assumption that a large amount of
sd-LDL was  present in the LDL fraction when the LDL-Rm value was
0.40 in the present study as well.
Statistical analysis
Data  are expressed as the mean ± standard deviation for contin-
uous variables and as percentages for discrete variables. Univariate
and multivariate regression analyses were performed to identify
independent predictors of LDL-Rm value. All variables correlated
with the LDL-Rm values at p < 0.05 in the univariate regression anal-
ysis were entered into the multivariate model. A receiver-operating
characteristic (ROC) analysis was  performed to determine the TRLs-
related marker cut-off values that indicated an LDL-Rm value ≥0.40.
Univariate and multivariate logistic regression analyses of variables
affecting patient characteristics with LDL-Rm values were ≥0.40
were performed in patients with LDL-C level <100 mg/dL. A p-value
less than 0.05 was considered to indicate statistical signiﬁcance. All
statistical analyses were performed with the SPSS software pro-
gram (SPSS Inc., Chicago, IL, USA) for Windows (version 12.0.1).
ResultsFig. 1. Measurement of LDL-Rm value by lipoprotein polyacrylamide gel disk elec-
trophoresis. LDL-Rm, relative low-density lipoprotein migration; LDL, low-density
lipoprotein;  HDL, high-density lipoprotein; VLDL, very-low-density lipoprotein;
LDL-Rm  value calculated from densitometer analysis of polyacrylamide disk gel
electrophoresis; LDL-Rm value = b/a.
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he analysis. The patient characteristics and laboratory proﬁle are
hown in Table 1. The mean LDL-Rm value was 0.350 ± 0.029.
nivariate and multivariate regression analyses of indicators of
stimated LDL-particle size
No correlations were found between LDL-Rm value values and
ge CKD ≥ stage 3, or statin use. Male gender, presence of smok-
ng, hypertension, and diabetes mellitus were associated with high
DL-Rm values. LDL-Rm values were signiﬁcantly positively corre-
ated with body mass index (BMI), number of risk factors, serum
DL-C, TRLs-related markers, and CRP levels, and signiﬁcantly neg-
tively correlated with HDL-C levels. These variables which showed
 < 0.05 were entered into the multivariate regression model.
able 1
atient characteristics and laboratory proﬁle.
N = 645
Male/female, n (%) 445 (69)/200 (31)
Age  (years) 62 ± 14
BMI (kg/m2) 24.0 ± 3.9
Hypertension, n (%) 458 (71)
Diabetes mellitus, n (%) 181 (28)
HbA1c (%) 5.97 ± 0.76
Current smoking, n (%) 174 (27)
Dyslipidemia, n (%) 400 (62)
eGFR (ml/min/1.73 m2) 70.8 ± 18.4
CKD≥ stage 3, n (%) 135 (21)
Number of risk factors 3.5 ± 1.5
Coronary artery disease, n (%) 142 (22)
Concomitant drug, n(%)
Anti-plateletes 174 (27)
ACE inhibitors 52 (8)
ARBs 258 (40)
 blockers 135 (21)
Calcium channel blockers 297 (46)
Statins 297 (46)
Fibrate 12 (1.9)
Ezetimibe 11(1.7)
Colestimide 3 (0.5)
N = 645
Lipids and apolipoproeins
TC  (mg/dL) 195 ± 38
LDL-C (mg/dL) 109 ± 31
HDL-C (mg/dL) 58 ± 17
Non-HDL-C (mg/dL) 137 ± 34
apo A-1 (mg/dL) 146 ± 30
apo B (mg/dL) 90 ± 21
MDA-LDL (U/L) 110 ± 44
TRLs-related markers
TG  (mg/dL) 120 (87–176)
VLDL (%) 11 (8.0–16.0)
RLP-C (mg/dL) 5.3 (3.8–7.4)
apo C-II (mg/dL) 4.6 ± 2.1
apo C-III (mg/dL) 10.2 ± 3.8
Inﬂammatory markers
WBC  count (cell/l) 6096 ± 1630
CRP (mg/dl) 0.05 (0.03–0.12)
Estimated LDL-particle size
LDL-Rm value 0.350 ± 0.029
MI: body mass index; Hb: hemoglobin; eGFR: estimated glomerular ﬁltration rate;
KD: chronic kidney disease; In this analysis, risk factors were deﬁned as: age ≥65
ears, male, BMI  ≥25 kg/m2, current smoker, hypertension, diabetes mellitus, CKD
stage 3, and dyslipidemia. We  calculated the mean number of risk factors of the
ubjects of this study on the basis of the total numbers of risk factors that were
resent.  ACE: angiotensin-converting enzyme; ARB: angiotensin receptor broker;
C: total cholesterol; LDL: low-density lipoprotein; HDL: high-density lipoprotein;
po:  apolipoprotein; MDA-LDL: malondialdehyde-modiﬁed LDL; TG: triglyceride;
LDL:  very low-density lipoprotein; RLP: remnant-like particle; WBC: white blood
ell; CRP: C-reactive protein; LDL-Rm value: relative LDL migration measured by
olyacrylamide-gel elecrophoresis.ology 63 (2014) 60–68
As the TRLs-related markers constituted mutually confound-
ing factors, ﬁve multivariate regression models incorporating the
respective variables were established to carry out the analysis. All
multivariate regression analysis models showed that the serum
TRLs-related markers, HDL-C, and LDL-C levels were independent
and signiﬁcant indicators of LDL-Rm value in all of the subjects
(Table 2a).
Accordingly, we  performed univariate and multivariate regres-
sion analyses to identify indicators of LDL-Rm value in the subjects
whose LDL-C level was <100 mg/dL (Table 2b). The results showed
that male gender and presence of hypertension were signiﬁcantly
associated with high values of LDL-Rm. The LDL-Rm values were
signiﬁcantly positively correlated with BMI, number of risk factors,
the serum TRLs-related markers, and CRP levels, and signiﬁcantly
negatively correlated with the HDL-C levels. As a result, all multi-
variate regression analysis models showed the serum TRLs-related
markers, and HDL-C levels were identiﬁed as independent indica-
tors in LDL-Rm value.
Comparison  of the serum TRLs-related, and atherogenic markers
values  of the patients with LDL-C values <100 mg/dL according to
whether their LDL-Rm values were ≥ 0.40 or < 0.40
We compared the TRLs-related marker and atherogenic marker
levels of the subjects with LDL-C values <100 mg/dL accord-
ing to whether they had LDL-Rm values ≥0.40 or <0.40. The
difference in LDL-C values between the group that had LDL-
Rm values ≥0.40 and the group that had LDL-Rm <0.40 was
not signiﬁcant [79 (66–94) mg/dL vs. 85 (75–92) mg/dL]. The
serum TG [278 (205–331) mg/dL vs. 107 (874–145) mg/dL], RLP-
C [9.4 (7.9–13.7) mg/dL vs. 4.3 (3.3–5.7) mg/dL], %VLDL [24.0
(17.8–29.2)% vs. 11.0 (7.0–15.0)%], apo CII [5.7 (5.1–8.3) mg/dL vs.
3.6 (2.8–4.7) mg/dL], and apo C III [14.3 (11.2–17.4) mg/dL vs. 8.6
(7.2–10.3) mg/dL] values were signiﬁcantly higher in the LDL-Rm
≥0.40 group than in the LDL-Rm <0.40 group. The serum HDL-C
levels were signiﬁcantly lower in the LDL-Rm value ≥0.40 group
than in the LDL-Rm value <0.40 group [43 (39–54) mg/dL vs. 59
(46–70) mg/dL]. Signiﬁcantly higher apo B [85 (80–91) mg/dL vs. 71
(64–78) mg/dL], MDA-LDL [108 (102–127) U/L vs. 79 (66–95) U/L],
and non-HDL-C [122 (113–138) mg/dL vs. 107 (97–116) mg/dL] lev-
els were found in the LDL-Rm ≥0.40 group than in the LDL-Rm <0.40
group.
As a result, a lower LDL-C/apoB ratio, a rough indicator of LDL-
particle size, [0.92 (0.85–1.05) vs. 1.17 (1.08–1.25)], and higher
MDA-LDL/apoB ratio, extent of oxidative modiﬁcation of LDL-
particles [5,14,15] [1.34 (1.16–1.42) vs. 1.14 (0.98–1.30)], were
found in the LDL-Rm value ≥0.40 group than in the LDL-Rm value
<0.40 group (Fig. 2). Fig. 3 shows a case of atherogenic dyslipidemia-
pattern with a serum LDL-C of <100 mg/dL and LDL-Rm of ≥0.40 on
PAGE.
Characteristics of patients with LDL-C level <100 mg/dL according
to whether their LDL-Rm value was ≥0.40 or <0.40
The presence of TG levels ≥150 mg/dL and presence of HDL-
C levels <40 mg/dL were signiﬁcantly higher in the LDL-Rm value
≥0.40 group than in the LDL-Rm value <0.40 group, but there were
no signiﬁcant differences between the two  groups according to gen-
der, age, BMI, whether hypertension was present, whether diabetes
mellitus was  present, HbA1c values, whether a current smoker,
whether CKD ≥ stage 3, whether CAD was present, or statin use
(Table 3a).Since  the univariate logistic regression analysis showed that the
presence of TG levels ≥150 mg/dL and the presence of HDL-C lev-
els of <40 mg/dL were signiﬁcantly associated with LDL-Rm values
≥0.40, these variables were entered into the multivariate logistic
S. Tani et al. / Journal of Cardiology 63 (2014) 60–68 63
Table  2a
Univariate and multivariate regression analyses of indicators estimated LDL-particle size (all cases).
All cases n = 645
Variables Univariate Multivariate 1 Multivariate 2 Multivariate 3 Multivariate 4 Multivariate 5
r p  ˇ p  ˇ p  ˇ p  ˇ p  ˇ p
Age 0.024 0.547
Male 0.128 0.001
BMI  0.191 <0.0001
Smoking 0.078 0.049
Hypertension 0.102 0.0095
Diabetes mellitus 0.077 0.0049
CKD ≥ stage 3 0.059 0.130
Numbers of risk factor 0.210 <0.0001
LDL-C 0.195 0.0001 0.123 0.0005 0.209 <0.0001 0.090 0.015 0.094 0.010  0.089 0.0079
HDL-C  −0.396 <0.0001 −0.229 <0.0001 −0.268  <0.0001 −0.331 <0.0001 −0.407 <0.0001 −0.555 <0.0001
TRLs-related  markers
TG*  0.531 <0.0001 0.418 <0.0001 – – – –
VLDL*  0.347 <0.0001 – 0.200 <0.0001 – – –
RLP-C*  0.449 <0.0001 – – 0.364 <0.0001 – –
apo  C-II 0.374 <0.0001 – – – 0.374 <0.0001 –
apo  C-III 0.385 <0.0001 – – – – 0.517 <0.0001
CRP*  0.142 0.0003
Statins use 0.077 0.059
Table 2b
Univariate and multivariate regression analyses of indicators estimated LDL-particle size (LDL-C <100 mg/dL).
LDL-C < 100mg dL n = 283
Variables Univariate Multivariate 1 Multivariate 2 Multivariate 3 Multivariate 4 Multivariate 5
r p  ˇ p  ˇ p  ˇ p  ˇ p  ˇ p
Age 0.057 0.369
Male  0.181 0.0043
BMI  0.161 0.017
Smoking  0.088 0.171
Hypertension 0.161 0.011
Diabetes  mellitus 0.063 0.405
CKD  ≥ stage 3 0.114 0.074
Numbers  of risk factor 0.248 <0.0001
LDL-C  0.053 0.405
HDL-C  −0.375 <0.0001 −0.180 0.0074 −0.202 0.009 −0.302 <0.0001 −0.412 <0.0001 −0.535 <0.0001
TRLs  -related markers
TG*  0.557 <0.0001 0.490 <0.0001 – – – –
VLDL*  0.403 <0.0001 – 0.287 <0.0001 – – –
RLP-C*  0.444 <0.0001 – – 0.399 <0.0001 – –
apo  C-II 0.369 <0.0001 – – – 0.410 <0.0001 –
apo  C-III 0.388 <0.0001 – – – – 0.517 <0.0001
CRP*  0.131 0.041
Statins  use 0.077 0.227
The abbreviations are the same as in Table 1; r: correlation coefﬁcient; : standard partial regression coefﬁcient; *log-transformed value was  used; male (0: female, 1:
male);  smoking (0: no, 1: yes); hypertension (0: no, 1: yes); diabetes mellitus (0: no, 1: yes); CKD ≥ stage 3 (0: no, 1: yes); statin use (0: no, 1: yes). Non-HDL-C, apo B, and
MDA-LDL were excluded as independent variables because of their multicolinearity with the LDL-C values. apo A-1 was  also excluded as independent variables because of
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egression model. The presence of a TG level ≥150 mg/dL was  a sig-
iﬁcant and independent predictor of an LDL-Rm value ≥0.40 in
atients with an LDL-C level <100 md/dL (Table 3b).
eceiver-operating characteristic analysis of indicators of LDL-Rm
alue  ≥0.40
An  ROC analysis was performed to determine the TRLs-related
arker cut-off values that indicated an LDL-Rm value ≥0.40, and
 good area under the curve (AUC) was obtained for both of them
Fig. 4). It was particularly noteworthy that all of the TRLs-related
arkers cut-off values for LDL-Rm value ≥0.40 were close to the
pper limit of the normal values that are used in routine clinical
ractice [16].tained by multivariate analyses were included.
Discussion
The results of this cross-sectional study showed that: 1) TRLs,
i.e. RLP-C and VLDL, which are related to TG-metabolism, and high
apoC-II and apoC-III values, as well as TG levels are independent
indicators of LDL conversion to small particles, and 2) the combined
evaluation of TRLs-related markers and LDL-Rm value may  become
a signiﬁcantly important tool in the risk stratiﬁcation of patients
with CAD, due to the simplicity of the measurement and calculation
in clinical settings.
Although statins signiﬁcantly decrease the incidence of CAD,
residual CAD risk remains high. A Cholesterol Treatment Trialists’
(CTT) meta-analysis of 14 large-scale clinical trials that veriﬁed
the efﬁcacy of statins showed that statins reduced CAD mortality
by approximately 20% [17]. Naturally, involvement by other risk
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he Québec Cardiovascular Study demonstrated that in patients
ith LDL-particle sizes of 25.5 nm or smaller, the CAD incidence
ncreased signiﬁcantly as the serum LDL-C level increased, whileents with LDL-C levels <100 mg/dL according to whether their LDL-Rm values were
tein migration; LDL, low-density lipoprotein; TG, triglyceride; RLP-C, remnant-like
MDA, malondialdehyde-modiﬁed.
in  patients having large LDL-particle sizes of 26.0 nm or greater, no
signiﬁcant difference in the CAD incidence was observed depending
on the absolute serum LDL-C level [19].
Now that the advent of statins has made it easy to manage
LDL-C, perhaps what we should do to further improve the out-
come of CAD is monitor LDL-particle size and attempt to reduce
the residual CAD risk. Estimation of the LDL-particle size may  be
essential for prevention of CAD, especially in high-risk patients
with multiple risk factors. The noteworthy result of this study is
having shown that LDL-Rm value, which can be easily measured in
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Fig. 3. A case of atherogenic dyslipidemia-pattern with a serum LDL-C of <100 mg/dL
and LDL-Rm value ≥4.0 on lipoprotein polyacrylamide gel disk electrophore-
sis  LDL, low-density lipoprotein; VLDL, very LDL; HDL, high-density lipoprotein;
LDL-Rm,  relative LDL migration. We present the case of a 57-year-old female
metabolic  syndrome patient who had a waist circumference of 92 cm,  hypertension,
a  low HDL cholesterol level, hypertriglyceridemia, and no history of atherosclerotic
cardiovascular  disease. The patient’s hypertension is being treated with antihy-
pertensive  medication, and we  are trying to decrease the hypertriglyceridemia
by  improving the patient’s lifestyle. The patient’s atherosclerosis-related marker
values  are as follows: b/a = LDL-Rm value, 0.47; total cholesterol, 166 mg/dL; LDL-
cholesterol, 73 mg/dL; HDL-cholesterol, 35 mg/dL; triglycerides, 279 mg/dL; VLDL
fraction, 22%; remnant-like particle cholesterol, 16.1 mg/dL; apolipoprotein (apo) C-
II, 4.2 mg/dL; apoC-III, 12.7 mg/dL; malondialdehyde-modiﬁed (MDA)-LDL, 99 U/L;
apoB, 85 mg/dL; LDL-cholesterol/apoB, 0.86; MDA-LDL/apoB, 1.16.
Table 3a
Characteristics of patients with LDL-C level <100 mg/dL according to whether their
LDL-Rm value was ≥0.40 or <0.40.
LDL-Rm value
≥0.40  n = 21
LDL-Rm  value
<0.40  n = 227
p-Value
Male/female, n (%) 17(81)/4 (19) 159 (70)/68 (30) 0.292
Age  (years) 61 ± 9.5 64 ± 14.4 0.390
BMI  (kg/m2) 23.7 ± 2.8 23.5 ± 4.1 0.807
Hypertension, n (%) 18 (86) 163 (72) 0.170
Diabetes mellitus, n (%) 8 (38) 66 (29) 0.387
HbA1c (%) 5.7 ± 0.6 5.5 ± 0.7 0.350
Current smoking (%) 5 (24) 30 (13) 0.155
CKD stage 3 ≥, n (%) 7 (33) 69 (30) 0.568
Coronary artery disease, n (%) 5 (24) 77 (34) 0.346
TG 150 mg/dL ≥, n (%) 18 (86) 52 (23) <0.0001
HDL-C 40 mg/dL<, (%) 6 (29) 25 (11) 0.020
Statin use 12 (57) 129 (57) 0.978
The abbreviations are the same as in Table 1.
Table 3b
Univariate and multivariate logistic regression analyses of variables affecting patient cha
Variables Univariate 
OR 95% CI 
Male/female 1.818 0.590–5.603 
Age ≥65 years 0.462 0.180–1.187 
BMI ≥25 kg/m2 0.893 0.332–2.399 
Hypertension 2.370 0.675–8.325 
Diabetes mellitus 1.501 0.595–3.795 
Current smoking 2.154 0.732–6.341 
CKD ≥ stage 3 1.145 0.443–2.962 
Coronary artery disease 0.609 0.215–1.724 
TG ≥ 150 mg/dL 20.192 5.722–71.255 
HDL-C  < 40 mg/dL 3.232 1.149–9.090 
Statin  use 1.013 0.410–2.500 
The abbreviations are the same as in Table 1. OR: odds ratio; CI: conﬁdence interval.ology 63 (2014) 60–68 65
clinical settings, is capable of serving as an indicator of LDL-particle
size. That was  corroborated by the fact that good TRLs-related
marker AUCs were obtained in an ROC analysis that stipulated LDL-
Rm values ≥0.40, and that their cut-off values were shown to be
similar to the upper limits of the standard values used in clinical
settings [16].
Moreover, surprisingly, there was  a group of subjects whose
LDL-C values were well controlled, i.e. <100 mg/dL, but whose LDL-
Rm values were ≥0.40, in which a larger amount of sd-LDL was
suggested than in the group with LDL-Rm values <0.40, which
occur as a result of high levels of atherogenic markers [20–24],
which have strong atherosclerotic cardiovascular disease-inducing
activity. This seems to mean that even when LDL-C has been aggres-
sively reduced by high-dose statin therapy, the fact that TG is an
independent predictor of CAD should be taken into account as a
contributing factor. In recent years a subanalysis of the PROVE IT-
TIMI 22 Trial [25] and post hoc analysis of the IDEAL and TNT Trials
[26] showed that hypertriglyceridemia is an independent predictor
of coronary events even in cases in which the target LDL-C level has
been reached as a result of statin therapy. The above observations
may strongly support our present results.
Study limitations/clinical implications
The ﬁrst limitation of this study was  that the subjects of the
study had risk factors for atherosclerotic cardiovascular disease,
and further study will be necessary to investigate whether the ﬁnd-
ings can be applied to the entire population. The second limitation
is that LDL-Rm value should always be viewed as the mean size
of aggregates of molecules having different LDL-particle sizes, and
since its relation to the absolute amount of sd-LDL is unknown, the
relationship between them should be clariﬁed in the future.
This  study focused on TG-metabolism, which is difﬁcult to con-
trol by drug therapy, in a hospital-based cross-sectional study that
closely reﬂected clinical practice, and demonstrated markers for
evaluating risk with a view to lipid management of atheroscle-
rosis patients. Thus, it seems that the ﬁnding that measurements
of LDL-Rm value, which can be conveniently performed in clinical
practice, are useful as a method of evaluating LDL-particle size will
make a major contribution to further prevention of atherosclerotic
cardiovascular disease.
Because  this was a cross-sectional study, it is impossible to draw
categorical conclusions in regard to causal relationships with the
individual results. Nevertheless, changes in LDL-particle size and
TRLs-related markers as a result of reducing the serum TG levels
are important as a means of evaluating the risk of atherosclerotic
diseases. Fig. 5 shows a case in which there was  a simultaneous
increase in LDL-particle size and improvement in atherogenic
racteristics with LDL-Rm values were ≥0.40.
Multivariate
p-Value OR 95% CI p-Value
0.298
0.109
0.822
0.178
0.390
0.164
0.760
0.350
<0.0001 18.763 5.285–66.620 <0.0001
0.026 2.200 0.699–6.929 0.178
0.978
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Fig. 4. Receiving-operating characteristics analysis of predictors of LDL-Rm value ≥0.40. LDL-Rm, relative low-density lipoprotein migration; TG, triglyceride; RLP-C, remnant-like particle cholesterol; VLDL, very low-density
lipoprotein; apo, apolipoprotein; AUC, area under the curve.
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Fig. 5. Effect of TG-lowering on LDL-Rm value. We encountered a 60-year-old male hypertension patient with hypertriglyceridemia who was being treated for hypertension.
We  recommended a 6-month lifestyle improvement program that included therapeutic diet modiﬁcation according to the American Heart Association/American College of
Cardiology  guideline [27]. Because elevated fasting serum TG levels ≥150 mg/dL persisted despite the lifestyle improvement, we prescribed fenoﬁbrate 80 mg/day. After 6
m respon
L sterol
a oprot
m
t
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T
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Ronths  of fenoﬁbrate therapy, the LDL-Rm value had decreased, and there were cor
DL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein chole
polipoprotein; MDA, malondialdehyde-modiﬁed; LDL-Rm, relative low-density lip
arkers as a result of reducing the serum TG levels of a hyper-
riglyceridemic patient.
onclusions
The  results suggest that the association between TG-metabolism
nd LDL-heterogeneity may  be closely associated with of the risk
f atherosclerotic cardiovascular disease. Combined evaluation of
RLs-related markers and LDL-Rm value may  become a signiﬁ-
antly important tool in the risk stratiﬁcation of patients with
therosclerotic cardiovascular disease especially CAD, due to the
implicity of the measurement and calculation in clinical settings.
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